Latest David B. Samadi Stories
NEW YORK, May 10, 2012 /PRNewswire/ -- Could it be that a remedy from thousands of years ago holds the secret to stopping prostate cancer? A newly published study furthers the exploration of caffeic acid phenethyl ester (CAPE) and its potential anticarcinogen and antioxidant properties. The demonstrated ability of CAPE to stop prostate cancer tumors from growing may soon have it earning a spot among other natural remedies for prostate cancer treatment. (Photo:...
NEW YORK, April 27, 2012 /PRNewswire/ -- The tomato has long been heralded for its lycopene antioxidant properties and now its close partner, oregano, is taking some credit in the fight against prostate cancer. New research shows the promising ability of oregano to destroy prostate cancer cells. (Photo: http://photos.prnewswire.com/prnh/20120427/NY96664) "Americans are very in tune with how diet affects health," says Dr. David Samadi, Vice Chairman, Department of Urology, and...
NEW YORK, April 13, 2012 /PRNewswire/ -- Dr. David Samadi, leading robotic prostatectomy surgeon, recently addressed an audience of colleagues, prostate cancer survivors, and their families at the Harmonie Club in New York City. Giving a very frank and detailed look at prostate cancer today, Dr. Samadi outlined why his revolutionary SMART (Samadi Modified Advanced Robotic Technique) Surgery is so successful in treating the disease and ensuring quality of life after prostate cancer....
NEW YORK, March 29, 2012 /PRNewswire/ -- As it turns out, new-to-the-market CyberKnife® Robotic Radiosurgery by Accuray is not robotic surgery at all. Rather, in the treatment of prostate cancer, CyberKnife® uses targeted high-dose radiation to attack prostate cancer cells. As Vice Chairman of the Department of Urology and Chief of Robotics and Minimally Invasive Surgery at Mount Sinai Medical Center, Dr. David Samadi worries that CyberKnife® branding may mislead...
HACKENSACK, N.J., March 21, 2012 /PRNewswire-USNewswire/ -- HackensackUMC is the first hospital in New Jersey and the New York metropolitan area to perform a robotic-assisted cholecystectomy, gallbladder removal surgery, using a single incision through the belly button. This groundbreaking surgery combines medical expertise, advanced technology, and state-of-the-art hospital and surgical facilities. Over a million gallbladders are removed annually in the United States and 10,000...
COLUMBUS, Ohio, March 21, 2012 /PRNewswire-iReach/ -- Over the past year patients throughout the United States have been interviewed about their experience receiving radiation therapy for treatment of prostate cancer at urology-integrated prostate cancer centers. Overwhelmingly patients cited better coordination of care, superior levels of service and positive treatment outcomes as unqualified support for this particular health care model. Patient videos can be found at www.aksm.com....
NEW YORK, March 16, 2012 /PRNewswire/ -- In perfecting the science of medicine, advancements always face exhaustive scrutiny and opposition. Typically, these rigors focus on confirming the efficacy of a procedure or treatment to ensure it remains in the patient's best interest for healing or wellness. More recently, with heightened emphasis on government-funded healthcare, medical procedures such as robotic prostatectomy surgery for prostate cancer treatment are under fire for cost....
NEW YORK, March 13, 2012 /PRNewswire/ -- It's never too early to fight prostate cancer, according to new research linking male circumcision at birth and a reduced risk of prostate cancer. A recent study published in the Cancer journal shows circumcised men could be 15 percent less likely to develop prostate cancer as an adult. As New York's leading robotic prostate cancer surgeon, Dr. David Samadi, welcomes this close-to-home news in the battle against prostate cancer. (Photo:...
NEW YORK, March 7, 2012 /PRNewswire/ -- Good news for those in favor of the one and only prostate cancer screening blood test, the prostate-specific antigen (PSA), is coming from a decade-long prostate cancer research study in Europe. Researchers report as much as a 38 percent decline in prostate cancer deaths among those who undergo routine PSA screenings for prostate cancer. (Photo: http://photos.prnewswire.com/prnh/20120307/NY66280 ) Leading prostate cancer robotic surgeon,...
Leading Clinicians Highlight Value of PCA3 Testing at Europe's Largest Urology Event QUEBEC CITY, Feb. 29, 2012 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high value cancer diagnostic tests, announced that PROGENSA((R) )PCA3 prostate cancer diagnostic test has been featured in seven presentations by leading professors and researchers at the 27(th) annual European Association of Urology (EAU) congress in Paris....
